RU2018134948A3 - - Google Patents

Download PDF

Info

Publication number
RU2018134948A3
RU2018134948A3 RU2018134948A RU2018134948A RU2018134948A3 RU 2018134948 A3 RU2018134948 A3 RU 2018134948A3 RU 2018134948 A RU2018134948 A RU 2018134948A RU 2018134948 A RU2018134948 A RU 2018134948A RU 2018134948 A3 RU2018134948 A3 RU 2018134948A3
Authority
RU
Russia
Application number
RU2018134948A
Other languages
Russian (ru)
Other versions
RU2018134948A (ru
RU2733402C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018134948A3 publication Critical patent/RU2018134948A3/ru
Publication of RU2018134948A publication Critical patent/RU2018134948A/ru
Application granted granted Critical
Publication of RU2733402C2 publication Critical patent/RU2733402C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16Halogenated acetic acids
    • C07C53/18Halogenated acetic acids containing fluorine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2018134948A 2016-03-07 2017-03-02 Бициклические арильные монобактамовые соединения и способы их применения для лечения бактериальных инфекций RU2733402C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662304447P 2016-03-07 2016-03-07
US62/304,447 2016-03-07
PCT/US2017/020303 WO2017155765A1 (en) 2016-03-07 2017-03-02 Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

Publications (3)

Publication Number Publication Date
RU2018134948A3 true RU2018134948A3 (enExample) 2020-04-08
RU2018134948A RU2018134948A (ru) 2020-04-08
RU2733402C2 RU2733402C2 (ru) 2020-10-01

Family

ID=59789685

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018134948A RU2733402C2 (ru) 2016-03-07 2017-03-02 Бициклические арильные монобактамовые соединения и способы их применения для лечения бактериальных инфекций

Country Status (12)

Country Link
US (1) US10407421B2 (enExample)
EP (1) EP3426248B1 (enExample)
JP (1) JP7034929B2 (enExample)
KR (1) KR102408800B1 (enExample)
CN (1) CN108778273B (enExample)
AU (1) AU2017228870B2 (enExample)
BR (1) BR112018067930B1 (enExample)
CA (1) CA3016341A1 (enExample)
MA (1) MA43811A (enExample)
MX (1) MX2018010878A (enExample)
RU (1) RU2733402C2 (enExample)
WO (1) WO2017155765A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7034929B2 (ja) 2016-03-07 2022-03-14 メルク・シャープ・アンド・ドーム・コーポレーション 二環式アリールモノバクタム化合物及び細菌感染症を治療するためにそれらを使用する方法
MA48994A (fr) 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
GEP20227406B (en) * 2017-10-02 2022-08-25 Merck Sharp & Dohme Chromane monobactam compounds for the treatment of bacterial infections
WO2019144969A1 (zh) * 2018-01-29 2019-08-01 南京明德新药研发股份有限公司 用于治疗细菌感染的单环β-内酰胺化合物
EP3826722A1 (en) 2018-07-24 2021-06-02 F. Hoffmann-La Roche AG Isoquinoline compounds and uses thereof
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2020098635A1 (zh) * 2018-11-13 2020-05-22 南京圣和药业股份有限公司 单环内酰胺化合物及其应用
EP3901150B1 (en) * 2018-12-18 2025-12-03 Shenzhen Optimum Biological Technology Co., Ltd Monocyclic beta-lactam compound for use in the treatment of pneumonia
CN110963967B (zh) * 2019-11-25 2021-02-12 武汉智顿科技发展有限公司 一种2-甲基-4-氨基喹啉的制备方法
CN111018777B (zh) * 2019-11-25 2021-02-12 武汉智顿科技发展有限公司 一种地喹氯铵的制备方法
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
WO2021121387A1 (zh) * 2019-12-19 2021-06-24 南京明德新药研发有限公司 化合物在制药中的应用
EP4146650A4 (en) 2020-09-01 2024-01-17 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAMASE INHIBITORS AND THEIR PRODUCTION
MX2023011616A (es) 2021-03-31 2023-10-30 Fedora Pharmaceuticals Inc Compuestos de lactivicina, su preparacion y uso como agentes antibacterianos.
EP4146651A4 (en) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS
AU2021473165B2 (en) * 2021-11-09 2025-05-22 Guangzhou HC New Drug Research Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING β-LACTAM COMPOUND AND USE THEREOF
JPWO2024101337A1 (enExample) * 2022-11-07 2024-05-16

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684722A (en) 1986-01-06 1987-08-04 E. R. Squibb & Sons, Inc. Monosulfactams
US5250691A (en) * 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
MY127641A (en) 1995-10-12 2006-12-29 Essential Therapeutics Inc Cephalosporin antibiotics
RU2269525C2 (ru) * 2000-08-10 2006-02-10 Бритиш Биотех Фармасьютикалс Лимитед Антибактериальные агенты
CA2783572C (en) 2005-12-07 2016-08-09 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
CN101765585B (zh) 2007-06-12 2017-03-15 尔察祯有限公司 抗菌剂
CA2815821C (en) 2010-11-29 2015-07-07 Pfizer Inc. Monobactams useful for treating bacterial infections
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
US20140275007A1 (en) 2013-03-14 2014-09-18 Rempex Pharmaceuticals, Inc. Oxamazin antibiotics
PT3122745T (pt) 2014-03-24 2019-04-30 Novartis Ag Compostos orgânicos de monobactama para o tratamento de infeções bacterianas
JP7034929B2 (ja) 2016-03-07 2022-03-14 メルク・シャープ・アンド・ドーム・コーポレーション 二環式アリールモノバクタム化合物及び細菌感染症を治療するためにそれらを使用する方法

Also Published As

Publication number Publication date
BR112018067930A2 (pt) 2019-01-22
EP3426248A4 (en) 2019-07-10
BR112018067930B1 (pt) 2024-02-15
KR102408800B1 (ko) 2022-06-13
EP3426248B1 (en) 2023-11-15
JP2019507768A (ja) 2019-03-22
RU2018134948A (ru) 2020-04-08
WO2017155765A1 (en) 2017-09-14
MA43811A (fr) 2018-11-28
KR20180121948A (ko) 2018-11-09
CA3016341A1 (en) 2017-09-14
AU2017228870A1 (en) 2018-09-06
AU2017228870B2 (en) 2021-02-18
BR112018067930A8 (pt) 2023-04-11
CN108778273A (zh) 2018-11-09
CN108778273B (zh) 2022-06-17
US10407421B2 (en) 2019-09-10
EP3426248A1 (en) 2019-01-16
US20190071436A1 (en) 2019-03-07
JP7034929B2 (ja) 2022-03-14
MX2018010878A (es) 2018-11-09
RU2733402C2 (ru) 2020-10-01

Similar Documents

Publication Publication Date Title
RU2018134948A3 (enExample)
CN303622764S (enExample)
CN303538479S (enExample)
CN303537266S (enExample)
CN303536529S (enExample)
CN303536494S (enExample)
CN303685127S (enExample)
CN303679158S (enExample)
CN303536426S (enExample)
CN303536391S (enExample)
CN303661451S (enExample)
CN303660986S (enExample)
CN303645268S (enExample)
CN303644372S (enExample)
CN303536258S (enExample)
CN303639195S (enExample)
CN303635116S (enExample)
CN303629459S (enExample)
CN303628213S (enExample)
CN303536241S (enExample)
CN303536236S (enExample)
CN303619376S (enExample)
CN303610683S (enExample)
CN303608043S (enExample)
CN303597044S (enExample)